Molecular pathogenesis of tuber formation in tuberous sclerosis complex

被引:62
作者
Crino, PB
机构
[1] Univ Penn, Dept Neurol, Med Ctr, Philadelphia, PA 19104 USA
[2] Univ Penn, PENN Epilepsy Ctr, Med Ctr, Philadelphia, PA 19104 USA
关键词
D O I
10.1177/08830738040190091301
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Tuberous sclerosis complex results from mutations in the TSC1 (hamartin) and TSC2 (tuberin) genes. Tubers are cortical developmental malformations in patients with tuberous sclerosis complex that are associated with intractable epilepsy and are composed of histologically distinct cell types, including giant cells and dysplastic neurons. We recently showed that tubers can be dynamic lesions characterized by populations of cells undergoing proliferation, migration, and death. We demonstrate that there is cell-specific activation of the mammalian target of rapamycin (mTOR)/p70S6 kinase/ribosomal S6 cascade in tubers and that giant cells express activated (phosphorylated) p70S6 kinase and ribosomal S6 protein. These findings support impaired hamartin-and tuberin-mediated mTOR pathway regulation. Tubers likely form by constitutive activation of the mTOR cascade during brain development as a consequence of impaired hamartin or tuberin function.
引用
收藏
页码:716 / 725
页数:10
相关论文
共 56 条
  • [1] CD44 expression in tuberous sclerosis
    Arai, Y
    Takashima, S
    Becker, LE
    [J]. PATHOBIOLOGY, 2000, 68 (02) : 87 - 92
  • [2] Baron Y, 1999, AM J NEURORADIOL, V20, P907
  • [3] Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex
    Bolton, PF
    Park, RJ
    Higgins, JNP
    Griffiths, PD
    Pickles, A
    [J]. BRAIN, 2002, 125 : 1247 - 1255
  • [4] Hamartin and tuberin interaction with the G2/M cyclin-dependent kinase CDK1 and its regulatory cyclins A and B
    Catania, MG
    Mischel, PS
    Vinters, HV
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (07) : 711 - 723
  • [5] Embryonic neuronal markers in tuberous sclerosis: Single-cell molecular pathology
    Crino, PB
    Trojanowski, JQ
    Dichter, MA
    Eberwine, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (24) : 14152 - 14157
  • [6] New developments in the neurobiology of the tuberous sclerosis complex
    Crino, PB
    Henske, EP
    [J]. NEUROLOGY, 1999, 53 (07) : 1384 - 1390
  • [7] Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs
    Dabora, SL
    Jozwiak, S
    Franz, DN
    Roberts, PS
    Nieto, A
    Chung, J
    Choy, YS
    Reeve, MP
    Thiele, E
    Egelhoff, JC
    Kasprzyk-Obara, J
    Domanska-Pakiela, D
    Kwiatkowski, DJ
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (01) : 64 - 80
  • [8] Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma
    El-Hashemite, N
    Zhang, HB
    Henske, EP
    Kwiatkowski, DJ
    [J]. LANCET, 2003, 361 (9366) : 1348 - 1349
  • [9] Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling
    Gao, XS
    Zhang, Y
    Arrazola, P
    Hino, O
    Kobayashi, T
    Yeung, RS
    Ru, BG
    Pan, DJ
    [J]. NATURE CELL BIOLOGY, 2002, 4 (09) : 699 - 704
  • [10] TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth
    Gao, XS
    Pan, DJ
    [J]. GENES & DEVELOPMENT, 2001, 15 (11) : 1383 - 1392